Current and historical daily PE Ratio for AVRO (
Avrobio Inc
) from 2018 to Jun 10 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Avrobio stock (AVRO) PE ratio as of Jun 10 2024 is 2.14.
More Details
Avrobio Inc (AVRO) PE Ratio (TTM) Chart
Avrobio Inc (AVRO) PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Total 1246
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Avrobio PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-10 | 2.1 | 2024-04-05 | 1.8 |
| 2024-06-07 | 2.2 | 2024-04-04 | 1.9 |
| 2024-06-06 | 2.1 | 2024-04-03 | 1.9 |
| 2024-06-05 | 2.1 | 2024-04-02 | 1.9 |
| 2024-06-04 | 2.1 | 2024-04-01 | 1.9 |
| 2024-06-03 | 2.1 | 2024-03-28 | 1.9 |
| 2024-05-31 | 2.1 | 2024-03-27 | 4.7 |
| 2024-05-30 | 2.1 | 2024-03-26 | 4.7 |
| 2024-05-29 | 2.1 | 2024-03-25 | 4.5 |
| 2024-05-28 | 2.1 | 2024-03-22 | 4.7 |
| 2024-05-24 | 2.2 | 2024-03-21 | 4.6 |
| 2024-05-23 | 2.0 | 2024-03-20 | 4.7 |
| 2024-05-22 | 2.0 | 2024-03-19 | 4.7 |
| 2024-05-21 | 2.0 | 2024-03-18 | 4.8 |
| 2024-05-20 | 2.0 | 2024-03-15 | 4.8 |
| 2024-05-17 | 2.0 | 2024-03-14 | 4.7 |
| 2024-05-16 | 2.0 | 2024-03-13 | 4.8 |
| 2024-05-15 | 2.0 | 2024-03-12 | 4.7 |
| 2024-05-14 | 1.9 | 2024-03-11 | 4.8 |
| 2024-05-13 | 2.0 | 2024-03-08 | 4.8 |
| 2024-05-10 | 1.8 | 2024-03-07 | 4.8 |
| 2024-05-09 | 1.8 | 2024-03-06 | 5.0 |
| 2024-05-08 | 1.8 | 2024-03-05 | 4.8 |
| 2024-05-07 | 1.8 | 2024-03-04 | 4.8 |
| 2024-05-06 | 1.8 | 2024-03-01 | 4.9 |
| 2024-05-03 | 1.8 | 2024-02-29 | 4.8 |
| 2024-05-02 | 1.8 | 2024-02-28 | 4.9 |
| 2024-05-01 | 1.8 | 2024-02-27 | 4.8 |
| 2024-04-30 | 1.7 | 2024-02-26 | 4.8 |
| 2024-04-29 | 1.7 | 2024-02-23 | 4.7 |
| 2024-04-26 | 1.8 | 2024-02-22 | 4.8 |
| 2024-04-25 | 1.7 | 2024-02-21 | 4.8 |
| 2024-04-24 | 1.7 | 2024-02-20 | 4.8 |
| 2024-04-23 | 1.8 | 2024-02-16 | 4.8 |
| 2024-04-22 | 1.7 | 2024-02-15 | 4.8 |
| 2024-04-19 | 1.7 | 2024-02-14 | 4.8 |
| 2024-04-18 | 1.8 | 2024-02-13 | 4.8 |
| 2024-04-17 | 1.8 | 2024-02-12 | 4.8 |
| 2024-04-16 | 1.8 | 2024-02-09 | 4.9 |
| 2024-04-15 | 1.8 | 2024-02-08 | 4.8 |
| 2024-04-12 | 1.8 | 2024-02-07 | 4.9 |
| 2024-04-11 | 1.8 | 2024-02-06 | 4.8 |
| 2024-04-10 | 1.8 | 2024-02-05 | 4.8 |
| 2024-04-09 | 1.8 | 2024-02-02 | 4.7 |
| 2024-04-08 | 1.8 | 2024-02-01 | 4.7 |
Avrobio Inc (AVRO) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Avrobio Inc
NAICS : 325414
SIC : 2836
ISIN : US05455M1009
Description
Avrobio Inc is a clinical-stage gene therapy company. The company is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single-dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers